Barclays PLC Novo Cure LTD Put Options Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $97,604 - $158,587	1,300 Added 216.67%	1,900 $143,000
Q3 2021 Nov 09, 2021	SELL	$116.17 - $194.55 $1.95 Million - $3.27 Million	-16,800 Reduced 96.55%	600 $70,000
Q3 2020 Nov 12, 2020	SELL	$58.05 - $111.31 $1.16 Million - $2.23 Million	-20,000 Reduced 53.48%	17,400 $1.94 Million
Q2 2020 Aug 12, 2020	SELL	$57.2 - $74.41 $1.72 Million - $2.23 Million	-30,000 Reduced 44.51%	37,400 $2.22 Million
Q1 2020 May 13, 2020	BUY	$57.05 - $95.75 $2.72 Million - $4.57 Million	47,700 Added 242.13%	67,400 $4.54 Million
Q4 2019 Feb 10, 2020	BUY	$68.3 - $93.8 $696,660 - $956,760	10,200 Added 107.37%	19,700 $1.66 Million
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $6.19 Million - $9.78 Million	-100,000 Reduced 91.32%	9,500 $710,000
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $401,090 - $600,685	9,500 Added 9.5%	109,500 $6.92 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $3.2 Million - $5.61 Million	100,000 New	100,000 $4.82 Million

264

76.5M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.49B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.